Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if involved), nor does it represent the platform's stance.Authorization is required for any article reprints.
Recently, PersonGen announced the completion of a newRound Financing, its core pipeline has entered Phase II clinical trials. PersonGen is a high-tech enterprise led by Dr. Yang Lin and co-founded by a team of biopharmaceutical experts with over ten years of experience at top overseas cancer clinical treatment and research institutions. The company focuses on the development of tumor cell immunotherapy technologies and products as its primary goal, with clinical technical services as its main business.
Currently, PersonGen has multiple pipeline assets advancing at a globally leading level. Its core product, PA3-17, the world’s first autologous CAR-T therapy targeting CD7 to have received approval for registrational clinical trials, has been granted Orphan Drug Designation by both the U.S. FDA and the European Commission, and has been included in the “Breakthrough Therapy” program by China’s Center for Drug Evaluation (CDE). In the pivotal Phase II clinical trial for adult relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (R/R T-ALL/LBL), PA3-17 injection has demonstrated exceptional potential, with an objective response rate (ORR) of 85% in the Phase I registrational clinical trial and a minimal residual disease (MRD)-negative complete remission rate as high as 95%, showcasing superior efficacy and safety. In December 2025, PersonGen entered into a strategic partnership with Anke Biotechnology to fully accelerate the market launch of this product.
In October 2025, LV009 Injection, an in vivo cell therapy product independently developed by PersonGen, was administered to the first patient. This milestone signifies that cell therapy is poised to transition from “high-cost customization” to “scalable, standardized pharmaceutical production.” By directly generating CAR-T/NK cells in vivo, the preparation timeline can be shortened from several weeks to an immediate “off-the-shelf” product, substantially reducing production costs and patient financial burden. Leveraging breakthrough lentiviral vector technology, LV009 achieves highly efficient transfection of resting T cells and NK cells, enabling the simultaneous generation of CD19-targeted CAR-T and CAR-NK cells. This approach holds the potential to deliver a transformative breakthrough in the treatment of B-cell malignancies.
Also last year, the clinical trial application for UTAA09, a universal off-the-shelf chimeric antigen receptor (CAR)-T cell injection targeting CD19 based on Vδ1 T cells developed by PersonGen, was approved for clinical trials to treat adult relapsed/refractory acute B-lymphoblastic leukemia (B-ALL). UTAA09 is the first universal off-the-shelf CAR-T cell product submitted by PersonGen and also the world's first universal off-the-shelf CD19-UCAR-Vδ1 T cell product approved for Investigational New Drug (IND) application.Amid intensifying global competition in cell therapy, PersonGen has built an innovative pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases, leveraging its proprietary lentiviral vector optimization platform and targeted cell delivery system. The closing of this financing round not only underscores strong recognition from the capital markets of PersonGen’s team and technological leadership, but will also accelerate the translation of multiple “first-in-class” products from clinical development to commercialization.About PersonGen
PersonGen was established in 2010. Dr. Yang Lin, the company’s founder, Chairman, and CEO, received his Ph.D. from Sun Yat-sen University in 1998. He previously served as an adjunct professor at the MD Anderson Cancer Center in the United States and possesses over 20 years of R&D experience at top-tier global cancer research centers. In 2011, after being recognized as a Science and Technology Leading Talent in Suzhou Industrial Park, Dr. Yang returned to China to work full-time.Scan the QR code to join the groupMastering CAR-T Therapy, Stem Cell Therapy, and GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
